Details of the Drug Reposition

General Information of This Drug (ID: DMCNFZG)

• Drug Name: Anti-GD2-CAR engineered T cells (DMCNFZG)
• Drug Type: CAR T Cell Therapy

Information on Drug Reposition of This Drug

3 Phase 1 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Sarcoma	DISZDG3U	2A60-2C35	Phase 1	[1]
Osteosarcoma	DISLQ7E2	2B51	Phase 1	[1]
Neuroblastoma	DISVZBI4	2D11.2	Phase 1	[1]

References

• [1] ClinicalTrials.gov (NCT02107963) A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors